Pharma doctor spend pays off for branded scripts
Doctors receiving payments were almost twice as likely to prescribe three brand name gabapentinoids, study shows
Paying doctors speaker fees or shouting them a meal appear to have paid off for the marketers of brand name gabapentinoids, US research suggests.
Doctors who received pharma company payments were almost twice as likely to prescribe the branded versions of the drugs than those who received no money, says a research letter in JAMA Internal Medicine.
Researchers from Yale University and the University of Connecticut examined the association between pharma payments and physician prescribing of gabapentinoids.
They compared Medicare and Medicaid prescribing data from 2014-16 with Open Payments data, a public record of drug company payments and gifts to doctors.
